AMRN News - Candlesense

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

(NASDAQ:AMRN) -- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- -- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --

Clinical trials

16 days ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

(NASDAQ:AMRN) -- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -...

Are there any upcoming regulatory, reimbursement, or pricing developments that could amplify or constrain revenue growth from the newly emphasized indications? What are the implications of the ESC guideline endorsement for VASCEPA/VAZKEPA's market share versus competing EPA/DHA or PCSK9 therapies? How will the highlighted REDUCE-IT sub‑analyses affect Amarin's valuation and short‑term stock momentum?

Clinical trials

17 days ago

Applications open for Ameren bill payment assistance

Ameren Illinois customers have received nearly $58 million this year for bill assistance; new program offers additional support COLLINSVILLE, Ill., Aug. 25, 2025 /PRNewswire/ -- Income-qualified cu...

Utilities

22 days ago